Alto Neuroscience, Inc.
ANRO
$2.28
$0.010.44%
NYSE
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.20M | 5.83M | 5.16M | 4.43M | 2.12M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.00M | 18.89M | 18.34M | 14.39M | 11.77M |
| Operating Income | -17.00M | -18.89M | -18.34M | -14.39M | -11.77M |
| Income Before Tax | -15.20M | -16.78M | -16.03M | -13.42M | -11.22M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -15.20M | -16.78M | -16.03M | -13.42M | -11.22M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.20M | -16.78M | -16.03M | -13.42M | -11.22M |
| EBIT | -17.00M | -18.89M | -18.34M | -14.39M | -11.77M |
| EBITDA | -16.83M | -18.76M | -18.23M | -14.29M | -11.65M |
| EPS Basic | -0.57 | -0.62 | -0.60 | -0.76 | -2.97 |
| Normalized Basic EPS | -0.35 | -0.39 | -0.37 | -0.48 | -1.86 |
| EPS Diluted | -0.57 | -0.62 | -0.60 | -0.76 | -2.97 |
| Normalized Diluted EPS | -0.35 | -0.39 | -0.37 | -0.48 | -1.86 |
| Average Basic Shares Outstanding | 26.77M | 26.96M | 26.91M | 17.60M | 3.77M |
| Average Diluted Shares Outstanding | 26.77M | 26.96M | 26.91M | 17.60M | 3.77M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |